The nation of Zimbabwe has declined a significant US healthcare agreement worth $367m (272 million pounds) over five years because of the United States' request for sensitive information.
The decision was revealed after a internal memorandum dated December was disclosed, which showed Head of State Emmerson Mnangagwa felt the deal was "unbalanced".
A government spokesman has since explained that the United States was requesting genetic material for research and profit while was not willing to guarantee the resulting advantages from any future vaccines.
"We must now begin the challenging and unfortunate process of winding down our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the United States had provided more than $1.9bn in health funding to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has called for continued dialogue to reach a deal acceptable to all parties so the country's critical HIV treatment initiative can continue.
Broader Context
This rejection comes after a comparable situation in neighbouring Kenya, where a high court halted a related deal with the US following legal challenges were raised about the security of citizens' medical information.
Since resuming the presidency recently, US President Donald Trump has drastically cut foreign aid and closed the US Agency for International Development (USAID).
The agency had managed aid for the American government, but Trump claimed its spending was "inefficient" and his government was seeking government-to-government agreements to boost transparency and accountability.
As per reports, Sixteen nations in Africa have to date signed these new health pacts, constituting over $18.3bn of fresh investment.
Details of the Rejected Agreement
The funds for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"It is our view this collaboration could have provided significant advantages for Zimbabwean communities, particularly the 1.2 million presently on HIV treatment via US-supported initiatives," the Ambassador added.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"Zimbabwe was being asked to surrender its genetic material and health information indefinitely, without any equivalent promise of access to any scientific breakthroughs – such as new medicines or tests – that could result from that provided information," his statement read.
"Put simply, our nation would provide the basic resources for medical research with no assurance that the final treatments would be available to our people should a new pandemic emerge."
Sovereignty and Global Health
Mangwana further noted that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were upending structures previously established through the global organization.
Mangwana cited its Pathogen Access and Benefit Sharing framework designed to manage future pandemics.
"This framework is designed to guarantee that when a country provides its information, the resulting advantages – including medicines and cures – are shared equitably, not monopolised solely by those with the resources to create them."
These objections regarding the US deal "must not be interpreted as anti-American sentiment," he added.
"We welcome continued dialogue with our US partners on how subsequent collaboration might be arranged in a manner that honours the independence and dignity of each country."
Health Experts Response
A leading public health body expressed it acknowledged the official position, but recommended that talks must proceed since much of the country's Aids initiatives relied on international support.
"Where specific concerns exist, such as those involving data governance or implementation frameworks, these can often be addressed through detailed discussion and mutually agreed protections," the group commented.
The situation emphasises the complex tensions between accepting much-needed international aid and safeguarding a country's data in an ever more data-driven world.